Anlotinib effectively inhibited the proliferation, migration, and invasion of human GBM cells (A172, U87, U251) in a dose-dependent manner through the mediation of the Janus kinase 2 (JAK2) / signal transducer and activator of transcription 3 (STAT3) signaling pathway [24]. Here, JAK2 is linked to glioblastoma.